Kiora PharmPharmticals(纳斯达克：KPRX-GET Rating)和Mallinckrodt(OTCMKTS：MNKKQ-GET Rating)都是小盘医疗公司，但哪一家是优势业务？我们将根据分析师推荐的盈利能力、风险、机构所有权、估值、股息和收益对这两家公司进行对比。
热门资讯> 正文
财务调查：Kiora制药公司(纳斯达克代码：KPRX)和Mallinckrodt公司(场外市场代码：MNKKQ)
2022-07-07 16:11
Kiora Pharmaceuticals (NASDAQ:KPRX – Get Rating) and Mallinckrodt (OTCMKTS:MNKKQ – Get Rating) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, risk, institutional ownership, valuation, dividends and earnings.
Volatility & Risk
波动性与风险
Get
到达
Kiora Pharmaceuticals
Kiora制药公司
alerts:
警报：
Kiora Pharmaceuticals has a beta of 0.82, suggesting that its share price is 18% less volatile than the S&P 500. Comparatively, Mallinckrodt has a beta of 3.02, suggesting that its share price is 202% more volatile than the S&P 500.
Kiora PharmPharmticals的贝塔系数为0.82，表明其股价的波动性比标准普尔500指数低18%。相比之下，Mallinckrodt的贝塔系数为3.02，这表明其股价的波动性比标准普尔500指数高202%。
Analyst Recommendations
分析师建议
This is a summary of recent recommendations for Kiora Pharmaceuticals and Mallinckrodt, as reported by MarketBeat.com.
据MarketBeat.com报道，这是对Kiora制药公司和Mallinckrodt公司最近建议的摘要。
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Kiora Pharmaceuticals | 0 | 0 | 2 | 0 | 3.00 |
| Mallinckrodt | 0 | 0 | 0 | 0 | N/A |
| 销售评级 | 保持评级 | 购买评级 | 强劲的买入评级 | 评级分数 | |
| Kiora制药公司 | 0 | 0 | 2 | 0 | 3.00 |
| 马林克罗德 | 0 | 0 | 0 | 0 | 不适用 |
Kiora Pharmaceuticals presently has a consensus price target of $2.00, indicating a potential upside of 330.48%. Given Kiora Pharmaceuticals' higher probable upside, equities research analysts plainly believe Kiora Pharmaceuticals is more favorable than Mallinckrodt.
Kiora PharmPharmticals目前的共识目标价为2.00美元，表明潜在上涨330.48%。鉴于Kiora PharmPharmticals更有可能上行，股票研究分析师显然认为Kiora PharmPharmticals比Mallinckrodt更有利。
Profitability
盈利能力
This table compares Kiora Pharmaceuticals and Mallinckrodt's net margins, return on equity and return on assets.
该表比较了Kiora制药公司和Mallinckrodt公司的净利润率、股本回报率和资产回报率。
| Net Margins | Return on Equity | Return on Assets | |
| Kiora Pharmaceuticals | N/A | -131.92% | -79.71% |
| Mallinckrodt | -32.36% | -80.40% | -4.00% |
| 净利润率 | 股本回报率 | 资产回报率 | |
| Kiora制药公司 | 不适用 | -131.92% | -79.71% |
| 马林克罗德 | -32.36% | -80.40% | -4.00% |
Institutional and Insider Ownership
机构和内部人持股
29.7% of Kiora Pharmaceuticals shares are held by institutional investors. Comparatively, 4.1% of Mallinckrodt shares are held by institutional investors. 58.2% of Kiora Pharmaceuticals shares are held by insiders. Comparatively, 3.6% of Mallinckrodt shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Kiora PharmPharmticals 29.7%的股份由机构投资者持有。相比之下，机构投资者持有Mallinckrodt 4.1%的股份。Kiora PharmPharmticals 58.2%的股份由内部人士持有。相比之下，Mallinckrodt 3.6%的股份由内部人士持有。强大的机构持股表明，对冲基金、捐赠基金和大型基金管理公司相信，一家公司的长期表现将好于大盘。
Earnings & Valuation
收益与估值
This table compares Kiora Pharmaceuticals and Mallinckrodt's top-line revenue, earnings per share and valuation.
该表格比较了Kiora制药公司和Mallinckrodt的营收、每股收益和估值。
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Kiora Pharmaceuticals | $10,000.00 | 588.37 | -$16.40 million | ($1.53) | -0.30 |
| Mallinckrodt | $2.21 billion | 0.00 | -$717.40 million | N/A | N/A |
| 总收入 | 价格/销售额比 | 净收入 | 每股收益 | 市盈率 | |
| Kiora制药公司 | $10,000.00 | 588.37 | -1,640万美元 | ($1.53) | -0.30 |
| 马林克罗德 | 22.1亿美元 | 0.00 | -7.174亿美元 | 不适用 | 不适用 |
Kiora Pharmaceuticals has higher earnings, but lower revenue than Mallinckrodt.
Kiora PharmPharmticals的收益高于Mallinckrodt，但营收低于Mallinckrodt。
Summary
摘要
Kiora Pharmaceuticals beats Mallinckrodt on 7 of the 11 factors compared between the two stocks.
Kiora PharmPharmticals在两只股票比较的11个因素中有7个超过了Mallinckrodt。
About Kiora Pharmaceuticals (Get Rating)
Kiora制药公司简介(获取评级)
Kiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, develops and commercializes therapies for the treatment of ophthalmic diseases in the United States. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 1 clinical trial that acts as a photoswitch to restore vision in patients with inherited and age-related degenerative retinal diseases. The company is also developing KIO-101, an eye drop that is in Phase 2 clinical trial for the treatment of ocular presentation of rheumatoid arthritis, as well as for treating non-infectious posterior uveitis; and KIO-201, an eye drop, which is in Phase 3 clinical trial for treating patients undergoing PRK surgery for corneal wound repair after refractive surgery. The company was formerly known as Eyegate Pharmaceuticals, Inc. and changed its name to Kiora Pharmaceuticals, Inc. in November 2021. Kiora Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Salt Lake City, Utah.
Kiora制药公司是一家临床阶段的专业制药公司，在美国开发和销售治疗眼科疾病的疗法。它的主要产品是KIO-301，这是一种潜在的恢复视力的小分子，正在进行一期临床试验，作为一种光开关来恢复遗传性和年龄相关的退行性视网膜疾病患者的视力。该公司还在开发KIO-101眼药水和KIO-201眼药水，KIO-101眼药水处于第二阶段临床试验，用于治疗类风湿性关节炎的眼部表现，以及治疗非传染性后葡萄膜炎；KIO-201眼药水处于第三阶段临床试验，用于治疗PRK手术患者屈光手术后的角膜伤口修复。该公司前身为EyeGate制药公司，并于2021年11月更名为Kiora制药公司。Kiora制药公司成立于1998年，总部设在犹他州盐湖城。
About Mallinckrodt (Get Rating)
关于马林克洛特(获取评级)
Mallinckrodt plc develops, manufactures, markets, and distributes specialty pharmaceutical products and therapies in the United States, Europe, the Middle East, Africa, and internationally. It operates in two segments, Specialty Brands and Specialty Generics. The company markets branded pharmaceutical products for autoimmune and rare diseases in the areas of neurology, rheumatology, nephrology, ophthalmology, pulmonology, and oncology; immunotherapy and neonatal respiratory critical care therapies; analgesics; cultured skin substitutes; and gastrointestinal products. It offers Acthar Gel, a repository corticotropin injection for rheumatoid arthritis, infantile spasms, systemic lupus erythematosus, multiple sclerosis, systemic dermatomyositis, symptomatic sarcoidosis, severe acute and chronic allergic, and inflammatory diseases; INOmax, a vasodilator to enhance oxygenation and reduce the need for extracorporeal membrane oxygenation; Therakos photopheresis, an immunotherapy treatment platform; Amitiza for constipation; and StrataGraft for the treatment of adults with deep partial-thickness burns. The company is also developing Terlipressin for the treatment of hepatorenal syndrome; and SLN 501 is a ribonucleic acid silencing therap. In addition, it provides specialty generic drugs and active pharmaceutical ingredients. The company markets its branded products to physicians, respiratory therapists, pharmacists, pharmacy buyers, hospital procurement departments, ambulatory surgical centers, and specialty pharmacies. Mallinckrodt plc has collaboration with Silence Therapeutics plc to develop and commercialize ribonucleic acid interference drug targets. The company was founded in 1867 and is based in Dublin, Ireland. On October 12, 2020, Mallinckrodt plc, along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.
Mallinckrodt公司在美国、欧洲、中东、非洲和国际上开发、制造、营销和分销特种药物和疗法。它分为两个部分，专业品牌和专业仿制药。该公司在神经科、风湿科、肾脏科、眼科、肺科和肿瘤科；免疫疗法和新生儿呼吸系统危重护理疗法；止痛药；培养皮肤替代品和胃肠产品等领域销售针对自身免疫和罕见疾病的品牌药品。它提供Acthar Gel，一个治疗类风湿关节炎、婴儿痉挛、系统性红斑狼疮、多发性硬化症、系统性皮肌炎、症状性结节病、严重急性和慢性过敏以及炎症性疾病的促肾上腺皮质激素注射剂库；INOmax，一种血管扩张剂，用于增强氧合，减少体外膜氧合的需要；Therakos Photoopparsis，一个免疫治疗平台；Amitia，用于便秘；以及StrataGraft，用于治疗成人深Ⅱ度烧伤。该公司还在开发用于治疗肝肾综合征的特利加压素；SLN 501是一种核糖核酸沉默疗法。此外，它还提供特种仿制药和活性药物成分。该公司向内科医生、呼吸治疗师、药剂师、药房买家、医院采购部、门诊外科中心和专业药店推销其品牌产品。Mallinckrodt plc与Silence Treeutics plc合作开发核糖核酸干扰药物靶标并将其商业化。该公司成立于1867年，总部设在爱尔兰都柏林。2020年10月12日，Mallinckrodt plc及其附属公司根据破产法第11章向美国特拉华州地区破产法院提交了自愿重组请愿书。
Receive News & Ratings for Kiora Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kiora Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
获得Kiora制药日报的新闻和评级-在下面输入您的电子邮件地址，通过MarketBeat.com的免费每日电子邮件时事通讯接收对Kiora制药和相关公司的最新新闻和分析师评级的每日简要摘要。
推荐文章
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
